Literature DB >> 21283925

Disease and treatment burden of psoriasis: examining the impact of biologics.

Kalindi Raval1, Jennifer H Lofland, Heidi Waters, Catherine Tak Piech.   

Abstract

Plaque psoriasis is a chronic, inflammatory skin disease that can be difficult to treat. Traditional systemic agents, topical agents, phototherapy and biologic therapies can be used for patients with psoriasis. The authors reviewed published results from a variety of sources in order to better understand the effects of psoriasis treatments on patient satisfaction, patient adherence, healthcare resource utilization and productivity. Patients with psoriasis consider many factors when evaluating therapies, including the time for the therapy to be effective, cosmetic issues common with topical therapies and travel to and from phototherapy centers. Satisfaction with and adherence to biologic therapies appears to be greater than for traditional therapies. Although biologic therapies are generally more expensive than are traditional, these agents may contribute to decreased healthcare utilization and increased productivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21283925

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  8 in total

1.  Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study).

Authors:  Alessandra Narcisi; Nicoletta Bernardini; Diego Orsini; Magda D'Agostino; Catia De Felice; Alessandro Di Stefani; Valentina Carboni; Antonio Costanzo; Claudio Mastroianni
Journal:  Postepy Dermatol Alergol       Date:  2020-07-16       Impact factor: 1.837

2.  The costs of psoriasis medications.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2013-12-13

3.  How much of the productivity losses among psoriasis patients are due to psoriasis.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  BMC Health Serv Res       Date:  2015-03-04       Impact factor: 2.655

4.  Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.

Authors:  Vassilis Fragoulakis; Efklidis Raptis; Elli Vitsou; Nikolaos Maniadakis
Journal:  Clinicoecon Outcomes Res       Date:  2015-01-08

Review 5.  A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus.

Authors:  R Strohal; J C Prinz; G Girolomoni; A Nast
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-09-14       Impact factor: 6.166

6.  Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

Authors:  K A Papp; K Barber; R Bissonnette; M Bourcier; C W Lynde; Y Poulin; J Shelton; K Garces; J Toole; M Poulin-Costello
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-21       Impact factor: 6.166

7.  Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort.

Authors:  Alexander Egeberg; Kyoungah See; Alyssa Garrelts; Russel Burge
Journal:  BMC Dermatol       Date:  2020-05-20

8.  Aspects concerning patient adherence to anti-TNFα therapy in psoriasis: A decade of clinical experience.

Authors:  Madalina Mocanu; Mihaela-Paula Toader; Elena Rezus; Tatiana Taranu
Journal:  Exp Ther Med       Date:  2019-09-16       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.